amgen glp-1 obesity drug market potential 2025 GLP-1 Receptor Agonist Market Size

Tirzepatide is redefining obesity & diabetes care. Dual GIP GLP 1 action deeper weight loss, stronger metabolic control, and emerging benefits from OSA to cardiometabolic risk. The era of multi pathway incretin therapy has Compare GLP 1 Options Ozempic v Mounjaro WeightWatchers WW USA GLP 1 receptor agonists are no longer just a diabetes medication and updated guidance reflects that. The SELECT trial demonstrated a 20% reduction in MACE in patients with obesity and established cardiovascular disease, Oral GLP 1 Agonists: Simplifying the Future of Metabolic Care While injectable GLP 1 therapies have made major strides, research is now accelerating around oral optionslike semaglutide (Rybelsus)to offer easier, more accessible treatment for GLP 1 receptor agonists for type 2 diabetes and weight management GLP 1 plus therapy can reduce heavy drinking National Institutes of Health (NIH)